Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.
Older women with acute leukemia still face treatment gaps even when gentler options exist, highlighting systemic biases that require deliberate corrective effort.
This Medicare fee-for-service claims analysis of 12,154 older AML patients ineligible for intensive induction reveals substantial treatment inequity: 53.6% received no AML-directed therapy, with female sex and greater age independently predicting undertreatment even after venetoclax became standard of care. No significant racial disparities were identified, but the persistent age and sex gaps highlight the need for conscious efforts to ensure equitable access to VEN+HMA therapy and clinical trial representation among the most vulnerable AML population.
What the study was
- Study design
- retrospective_cohort
- Population
- Medicare AML patients aged >=75 or unfit for intensive induction therapy
- Sample size
- 12154
- Category
- Public Health
- Maturity
- Validated
- Journal
- Leuk Lymphoma
Why it surfaced
Large Medicare database analysis (12,154 patients) revealing sex-based inequity in AML treatment uptake; Yale/AbbVie/Genentech collaboration; highly relevant to hematologic malignancies watchlist; published in Leukemia & Lymphoma; actionable for policy and clinical practice; corrected from HIGH to STANDARD: score 7 with UNDERSERVED_POPULATION flag (does not auto-elevate to HIGH).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.